IRWD vs OPTU Comparison

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Optimum's assets were brought together when Altice Europe acquired US cable companies Suddenlink in 2015 and Cablevision in 2016. The Suddenlink business, which management calls the "West," provides television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. The Cablevision portion, dubbed the "East," provides comparable services to about 5.5 million homes and businesses in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Optimum, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018.